Genscript Biotech Corporation (HKG:1548)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
41.40
+0.94 (2.32%)
Sep 23, 2026, 9:29 AM HKT

Genscript Biotech Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-636.71-532.832,962-95.48-226.85-358.71
Depreciation & Amortization
78.8373.375.7171.8861.1845.86
Other Amortization
0.740.741.962.173.071.92
Loss (Gain) From Sale of Assets
1.710.871.190.690.770.91
Asset Writedown & Restructuring Costs
--45.5111.6611.48-
Loss (Gain) From Sale of Investments
392.36391.56-0.19-2.433.64-0.53
Loss (Gain) on Equity Investments
281.93320.3839.071.380.03-
Stock-Based Compensation
15.814.7976.5260.5965.1539.69
Provision & Write-off of Bad Debts
-1.33-1.336.564.781.150.93
Other Operating Activities
53.1659.87-3,020264.61-204.38-9.51
Change in Accounts Receivable
-24.49-16.4995.46-116.9938.071.57
Change in Inventory
-8-8.58-10.53-3.93-19.53-15.14
Change in Accounts Payable
-9.46.9515.99-37.0325.588.07
Change in Unearned Revenue
23.321.98-35.75100.776.763.54
Change in Other Net Operating Assets
-28.3214.3120.28-29.74113.59144.6
Operating Cash Flow
139.57325.5275.65-286.91-120.29-136.79
Operating Cash Flow Growth
-38.89%330.32%----

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-91.51-82.13-195.79-252.45-216.11-133.04
Sale of Property, Plant & Equipment
0.670.370.240.240.090.27
Sale (Purchase) of Intangibles
-1.53-1.76-1.24-4.05-2.27-4.35
Investment in Securities
14.1-83.14-806-101.72-219.75-82.44
Other Investing Activities
17.64-5.29-453.570.25-5.257.02
Investing Cash Flow
-60.63-171.95-1,456-357.73-443.3-212.55

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
-219.09102.6174.3933.0626.04
Long-Term Debt Repaid
--142.34-67.74-34.06-7.39-74.94
Lease Payments
-9.79-8.99-9.58-9.45-6.93-3.72
Total Debt Repaid
-214.65-142.34-67.74-34.06-7.39-74.94
Net Debt Issued (Repaid)
19.6276.7434.8640.3325.67-48.89
Issuance of Common Stock
2.356.0213.4917.65228.13951.23
Other Financing Activities
4.81-2.5118.171,010165.52-0.19
Financing Cash Flow
-175.84-144.8966.521,068419.32902.14

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
0.051.82-0.22-1.22-12.7-0.89
Net Cash Flow
-96.8510.5-1,314422.4-156.97551.91

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
48.06243.39-120.14-539.36-336.41-269.83
Free Cash Flow Growth
-62.56%-----
Free Cash Flow Margin
5.69%25.36%-20.21%-96.23%-53.76%-55.06%
Free Cash Flow Per Share
0.020.11-0.06-0.26-0.16-0.13
Levered Free Cash Flow
94.85-67.82425.25-305.28-342.98-176.43
Unlevered Free Cash Flow
103.91-57.01430.27-301.7-334.69-174.95
Free Cash Flow After Leases
38.28234.4-129.72-548.81-343.33-273.55

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
11.9711.544.683.192.041.58
Cash Income Tax Paid
48.329.2416.62.66-0.660.71
Change in Working Capital
-46.91-1.8285.44-86.91164.47142.65